Florence Coulet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Florence Coulet has a total of 403 co-authors. Here are the top co-authors by number of shared publications:
- Etienne Rouleau
Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
14 shared publications - Laurent Castera
Université Paris Cité, UMR1149 (CRI), INSERM, Paris, France
14 shared publications - Angelina Legros
Laboratoire de biologie et de génétique du cancer, Centre François Baclesse, Caen, France
13 shared publications - Aurore Tranchant
Laboratoire de biologie et de génétique du cancer, Centre François Baclesse, Caen, France
13 shared publications - Aurélie Dumont
Unité d'Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France
13 shared publications - Catherine Genestie
Department of Pathology Gustave‐Roussy Villejuif France
13 shared publications
Latest Publications
- 10 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600808
Beyond Heritable PAH: Pulmonary Hypertension in Genetic Syndromes
Pulmonary hypertension (PH) may complicate a broad range of genetic syndromes beyond the established spectrum of heritable pulmonary arterial hypertension. Although these conditions are individually rare, together they represent an emerging field at the crossroads of developmental biology, vascular medicine, and precision genomics. In many cases, PH may be the presenting feature or may remain unrecognized because it occurs within complex multisystem disorders involving congenital heart disease, developmental lung abnormalities, parenchymal lung disease, vascular malformations, or extra-pulmonary manifestations. Recent advances in human genetics have expanded the spectrum of genes and syndromes associated with PH, including disorders involving altered lung and vascular development, dysregulated hypoxia signaling, smooth muscle dysfunction, chromosomal abnormalities, and syndromic vasculopathies. In this review, we summarize the main genetic syndromes associated with PH and discuss their underlying mechanisms, clinical phenotypes, diagnostic clues, and therapeutic implications. We paid particular attention to conditions that illustrate the marked heterogeneity of syndromic PH such as FLNA -related disorders, neurofibromatosis type 1, Noonan syndrome, Down syndrome, Alagille syndrome, Cantú syndrome, Chuvash polycythaemia, cobalamin C deficiency, multisystemic smooth muscle dysfunction syndrome, alveolar capillary dysplasia with misalignment of pulmonary veins, and Moya Moya syndrome.
- 10 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600808
Beyond Heritable PAH: Pulmonary Hypertension in Genetic Syndromes
Pulmonary hypertension (PH) may complicate a broad range of genetic syndromes beyond the established spectrum of heritable pulmonary arterial hypertension. Although these conditions are individually rare, together they represent an emerging field at the crossroads of developmental biology, vascular medicine, and precision genomics. In many cases, PH may be the presenting feature or may remain unrecognized because it occurs within complex multisystem disorders involving congenital heart disease, developmental lung abnormalities, parenchymal lung disease, vascular malformations, or extra-pulmonary manifestations. Recent advances in human genetics have expanded the spectrum of genes and syndromes associated with PH, including disorders involving altered lung and vascular development, dysregulated hypoxia signaling, smooth muscle dysfunction, chromosomal abnormalities, and syndromic vasculopathies. In this review, we summarize the main genetic syndromes associated with PH and discuss their underlying mechanisms, clinical phenotypes, diagnostic clues, and therapeutic implications. We paid particular attention to conditions that illustrate the marked heterogeneity of syndromic PH such as FLNA -related disorders, neurofibromatosis type 1, Noonan syndrome, Down syndrome, Alagille syndrome, Cantú syndrome, Chuvash polycythaemia, cobalamin C deficiency, multisystemic smooth muscle dysfunction syndrome, alveolar capillary dysplasia with misalignment of pulmonary veins, and Moya Moya syndrome.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (4) , e005626
Functional and Molecular Characterization of Novel GDF2 ( BMP9 ) and BMP10 Variants From the French PAH and HHT Cohorts
BACKGROUND: GDF2 (encoding BMP9) variants have been described in pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT), as well as a few BMP10 variants in PAH. The purpose of the present study was to develop a functional assay capable of discriminating benign from pathogenic variants and to characterize the underlying molecular mechanisms responsible for their loss of function. METHODS: We developed a single-step functional assay in which C2C12 cells stably expressing a BMP (bone morphogenetic protein)-responsive element upstream of a firefly luciferase reporter would be stimulated by the autocrine secretion of BMP9 or BMP10 variants produced by transfected expression plasmids. RESULTS: Using this functional assay, we reclassified all GDF2 variants and 2 out of 5 BMP10 variants identified in patients with PAH as likely pathogenic. In contrast, only 2 of the 4 GDF2 variants identified in suspected patients with HHT were found to be likely pathogenic; nevertheless, none of the patients met the diagnostic criteria for hereditary hemorrhagic telangiectasia. We also showed, using ELISAs and Western blots, that the loss of function of GDF2 and BMP10 variants was mostly due to altered processing (folding/stability defects). Moreover, we found that loss-of-function GDF2 variants impaired the secretion of BMP10, suggesting a potential dominant-negative mechanism. CONCLUSIONS: We developed a functional assay for GDF2 and BMP10 variants, enabling the reclassification of variants of unknown significance. Together, this study further supports the involvement of GDF2 and BMP10 as predisposing genes in PAH. This single-step assay will be transferable to clinical genetic laboratories and will improve diagnosis of patients with PAH and HHT.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (4) , e005626
Functional and Molecular Characterization of Novel GDF2 ( BMP9 ) and BMP10 Variants From the French PAH and HHT Cohorts
BACKGROUND: GDF2 (encoding BMP9) variants have been described in pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT), as well as a few BMP10 variants in PAH. The purpose of the present study was to develop a functional assay capable of discriminating benign from pathogenic variants and to characterize the underlying molecular mechanisms responsible for their loss of function. METHODS: We developed a single-step functional assay in which C2C12 cells stably expressing a BMP (bone morphogenetic protein)-responsive element upstream of a firefly luciferase reporter would be stimulated by the autocrine secretion of BMP9 or BMP10 variants produced by transfected expression plasmids. RESULTS: Using this functional assay, we reclassified all GDF2 variants and 2 out of 5 BMP10 variants identified in patients with PAH as likely pathogenic. In contrast, only 2 of the 4 GDF2 variants identified in suspected patients with HHT were found to be likely pathogenic; nevertheless, none of the patients met the diagnostic criteria for hereditary hemorrhagic telangiectasia. We also showed, using ELISAs and Western blots, that the loss of function of GDF2 and BMP10 variants was mostly due to altered processing (folding/stability defects). Moreover, we found that loss-of-function GDF2 variants impaired the secretion of BMP10, suggesting a potential dominant-negative mechanism. CONCLUSIONS: We developed a functional assay for GDF2 and BMP10 variants, enabling the reclassification of variants of unknown significance. Together, this study further supports the involvement of GDF2 and BMP10 as predisposing genes in PAH. This single-step assay will be transferable to clinical genetic laboratories and will improve diagnosis of patients with PAH and HHT.
- 18 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (6) , 2600770
Reply: FLNA loss-of-function variants in pulmonary hypertension: implications for genetic testing in congenital heart disease
Extract We thank M. Mora-Gómez and co-workers for their interest in our study describing the phenotype of patients with precapillary pulmonary hypertension (PH) associated with Filamin A (FLNA) loss-of-function pathogenic variants [1]. M. Mora-Gómez and co-workers report three additional cases of precapillary PH in paediatric and adult female patients, all of whom had a patent ductus arteriosus and a pathogenic heterozygous loss-of-function variant. Shareable abstract Pulmonary hypertension associated with pathogenic FLNA variants is characterised by developmental abnormalities affecting both the lungs and the heart, notably with a frequent association with congenital heart disease https://bit.ly/4mwUQKW
- 18 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (6) , 2600770
Reply: FLNA loss-of-function variants in pulmonary hypertension: implications for genetic testing in congenital heart disease
Extract We thank M. Mora-Gómez and co-workers for their interest in our study describing the phenotype of patients with precapillary pulmonary hypertension (PH) associated with Filamin A (FLNA) loss-of-function pathogenic variants [1]. M. Mora-Gómez and co-workers report three additional cases of precapillary PH in paediatric and adult female patients, all of whom had a patent ductus arteriosus and a pathogenic heterozygous loss-of-function variant. Shareable abstract Pulmonary hypertension associated with pathogenic FLNA variants is characterised by developmental abnormalities affecting both the lungs and the heart, notably with a frequent association with congenital heart disease https://bit.ly/4mwUQKW
- 19 February 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (4) , 2502322
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with an estimated prevalence of one in 5000 to one in 7000. Pathogenic variants in three genes, endoglin ( ENG ), activin receptor-like kinase 1 ( ACVRL1 ) and mothers against decapentaplegic homolog 4 ( SMAD4 ), all part of the transforming growth factor-β signalling pathway, account for over 90% of HHT cases. Clinically, HHT is characterised by recurrent epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and visceral arteriovenous malformations (AVMs), most commonly affecting the lungs, liver and brain. Pulmonary hypertension (PH) is a recognised but heterogeneous complication of HHT, with reported prevalence ranging widely from 1.5% to 45%, depending on diagnostic methods and study populations. PH associated with HHT can result from distinct, and sometimes overlapping, pathophysiological mechanisms, including high cardiac output resulting from AVMs, either isolated or associated with left heart disease and precapillary PH, usually consistent with pulmonary arterial hypertension (PAH). Accurate haemodynamic classification by right heart catheterisation is essential to determine the predominant mechanism and guide appropriate therapeutic strategies. These may include embolisation or other management of AVMs, assessment for hepatic transplantation, administration of anti-angiogenic therapies such as anti-vascular endothelial growth factor agents or the use of PAH-approved drugs in selected patients with precapillary involvement. Given the complexity of PH associated with HHT, optimal management requires a multidisciplinary approach within specialised centres experienced in both diseases. This review aims to provide a comprehensive overview of genetics, clinical phenotypes and the diagnostic and therapeutic challenges in PH associated with HHT.
- 19 February 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (4) , 2502322
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with an estimated prevalence of one in 5000 to one in 7000. Pathogenic variants in three genes, endoglin ( ENG ), activin receptor-like kinase 1 ( ACVRL1 ) and mothers against decapentaplegic homolog 4 ( SMAD4 ), all part of the transforming growth factor-β signalling pathway, account for over 90% of HHT cases. Clinically, HHT is characterised by recurrent epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and visceral arteriovenous malformations (AVMs), most commonly affecting the lungs, liver and brain. Pulmonary hypertension (PH) is a recognised but heterogeneous complication of HHT, with reported prevalence ranging widely from 1.5% to 45%, depending on diagnostic methods and study populations. PH associated with HHT can result from distinct, and sometimes overlapping, pathophysiological mechanisms, including high cardiac output resulting from AVMs, either isolated or associated with left heart disease and precapillary PH, usually consistent with pulmonary arterial hypertension (PAH). Accurate haemodynamic classification by right heart catheterisation is essential to determine the predominant mechanism and guide appropriate therapeutic strategies. These may include embolisation or other management of AVMs, assessment for hepatic transplantation, administration of anti-angiogenic therapies such as anti-vascular endothelial growth factor agents or the use of PAH-approved drugs in selected patients with precapillary involvement. Given the complexity of PH associated with HHT, optimal management requires a multidisciplinary approach within specialised centres experienced in both diseases. This review aims to provide a comprehensive overview of genetics, clinical phenotypes and the diagnostic and therapeutic challenges in PH associated with HHT.
- 11 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (6) , 2501796
Pulmonary hypertension in patients with Noonan syndrome
Background: Noonan syndrome is a RASopathy inherited in an autosomal dominant manner, mainly caused by gain-of-function variants activating the RAS/mitogen-activated protein kinase signalling pathway. Pulmonary hypertension (PH) may occur in Noonan syndrome, but its mechanisms, clinical characteristics and outcomes remain poorly defined. Methods: We analysed data from the French PH Network to characterise the phenotype of Noonan syndrome patients who develop PH, and conducted a systematic analysis of the literature. Results: Seven patients were identified from the French PH Network (male/female ratio 1.3:1), with a median (range) age at PH diagnosis of 9 (5–21) years. Genetic analysis revealed five pathogenic variants in PTPN11 and one in SHOC2 . Associated features included facial dysmorphism, growth retardation, atrial septal defect and pulmonary valve stenosis. Haemodynamics showed severe pre-capillary PH without acute vasodilator response: mean pulmonary arterial pressure 55 (40–78) mmHg, cardiac output 3.95 (3.12–4.95) L·min −1 and pulmonary vascular resistance 13 (10–15.3) WU. Computed tomography of the chest identified perivascular ground-glass opacities, mediastinal infiltration, dilated bronchial arteries, distal pulmonary vascular tortuosity and possible arteriovenous shunts. Five patients were treated with drugs approved for pulmonary arterial hypertension. Three patients died and one underwent lung transplantation. Explanted lungs revealed plexiform lesions associated with diffuse lymphangiectasia. 12 additional cases from the literature included seven with pre-capillary PH, four with post-capillary PH due to cardiomyopathy and one without right heart catheterisation. Conclusion: Pre-capillary and post-capillary PH may complicate the course of Noonan syndrome, potentially in association with congenital heart defects and multisystem manifestations. Further studies are needed to better delineate the phenotype of PH in patients with Noonan syndrome.
- 11 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (6) , 2501796
Pulmonary hypertension in patients with Noonan syndrome
Background: Noonan syndrome is a RASopathy inherited in an autosomal dominant manner, mainly caused by gain-of-function variants activating the RAS/mitogen-activated protein kinase signalling pathway. Pulmonary hypertension (PH) may occur in Noonan syndrome, but its mechanisms, clinical characteristics and outcomes remain poorly defined. Methods: We analysed data from the French PH Network to characterise the phenotype of Noonan syndrome patients who develop PH, and conducted a systematic analysis of the literature. Results: Seven patients were identified from the French PH Network (male/female ratio 1.3:1), with a median (range) age at PH diagnosis of 9 (5–21) years. Genetic analysis revealed five pathogenic variants in PTPN11 and one in SHOC2 . Associated features included facial dysmorphism, growth retardation, atrial septal defect and pulmonary valve stenosis. Haemodynamics showed severe pre-capillary PH without acute vasodilator response: mean pulmonary arterial pressure 55 (40–78) mmHg, cardiac output 3.95 (3.12–4.95) L·min −1 and pulmonary vascular resistance 13 (10–15.3) WU. Computed tomography of the chest identified perivascular ground-glass opacities, mediastinal infiltration, dilated bronchial arteries, distal pulmonary vascular tortuosity and possible arteriovenous shunts. Five patients were treated with drugs approved for pulmonary arterial hypertension. Three patients died and one underwent lung transplantation. Explanted lungs revealed plexiform lesions associated with diffuse lymphangiectasia. 12 additional cases from the literature included seven with pre-capillary PH, four with post-capillary PH due to cardiomyopathy and one without right heart catheterisation. Conclusion: Pre-capillary and post-capillary PH may complicate the course of Noonan syndrome, potentially in association with congenital heart defects and multisystem manifestations. Further studies are needed to better delineate the phenotype of PH in patients with Noonan syndrome.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Prospective collection used to train GIScar (n = 250)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Prospective collection used to train GIScar (n = 250)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Clinical collection used to validate GIScar (n = 469)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Clinical collection used to validate GIScar (n = 469)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
MGMC and GIScar scores among concordant and discordant HRD classification on the clinical collection (n = 469)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
MGMC and GIScar scores among concordant and discordant HRD classification on the clinical collection (n = 469)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Kaplan–Meier estimates of PFS stratified on Giscar HRD status among inconclusive status of MGMC (n = 43).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Kaplan–Meier estimates of PFS stratified on Giscar HRD status among inconclusive status of MGMC (n = 43).